{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:55:05Z","timestamp":1780538105069,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40263-022-00953-x","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T11:02:38Z","timestamp":1664449358000},"page":"1121-1131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-4225","authenticated-orcid":false,"given":"Michael","family":"Auer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Oftring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Rudzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zinganell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"953_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","volume":"70","author":"RA Rudick","year":"2013","unstructured":"Rudick RA, Polman CH, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70:172\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2013.598.","journal-title":"JAMA Neurol"},{"key":"953_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, AFFIRM Investigators, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med"},{"key":"953_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, SENTINEL Investigators, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323. https:\/\/doi.org\/10.1056\/NEJMoa044396.","journal-title":"N Engl J Med"},{"key":"953_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0165-5728(01)00253-3","volume":"115","author":"PA Calabresi","year":"2001","unstructured":"Calabresi PA, Prat A, Biernacki K, Rollins J, Antel JP. T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol. 2001;115:161\u20137. https:\/\/doi.org\/10.1016\/s0165-5728(01)00253-3.","journal-title":"J Neuroimmunol"},{"key":"953_CR5","doi-asserted-by":"publisher","first-page":"37459","DOI":"10.1074\/jbc.M305877200","volume":"278","author":"KJ Garton","year":"2003","unstructured":"Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem. 2003;278:37459\u201364. https:\/\/doi.org\/10.1074\/jbc.M305877200.","journal-title":"J Biol Chem"},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cardiores.2005.02.020","volume":"67","author":"RJR Singh","year":"2005","unstructured":"Singh RJR, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res. 2005;67:39\u201349. https:\/\/doi.org\/10.1016\/j.cardiores.2005.02.020.","journal-title":"Cardiovasc Res"},{"key":"953_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","volume":"227","author":"A Millonig","year":"2010","unstructured":"Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol. 2010;227:190\u20134. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.07.012.","journal-title":"J Neuroimmunol"},{"key":"953_CR8","doi-asserted-by":"publisher","first-page":"P675","DOI":"10.1055\/s-0029-1238768","volume":"36","author":"K Oppermann","year":"2009","unstructured":"Oppermann K, Pilz G, Wipfler P, Sulzer C, Afazel S, Haschke-Becher E, et al. Effect of natalizumab treatment on soluble adhesion molecules. Aktuelle Neurol. 2009;36:P675. https:\/\/doi.org\/10.1055\/s-0029-1238768.","journal-title":"Aktuelle Neurol"},{"key":"953_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-015-1417-0","volume":"129","author":"A Haarmann","year":"2015","unstructured":"Haarmann A, Nowak E, Dei\u00df A, van der Pol S, Monoranu CM, Kooij G, et al. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin \u03b1-4-transduced outside-in signaling. Acta Neuropathol. 2015;129:639\u201352. https:\/\/doi.org\/10.1007\/s00401-015-1417-0.","journal-title":"Acta Neuropathol"},{"key":"953_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.410380210","volume":"38","author":"HP Hartung","year":"1995","unstructured":"Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol. 1995;38:186\u201393. https:\/\/doi.org\/10.1002\/ana.410380210.","journal-title":"Ann Neurol"},{"key":"953_CR11","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93:e1452\u201362. https:\/\/doi.org\/10.1212\/WNL.0000000000008243.","journal-title":"Neurology"},{"key":"953_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","volume":"31","author":"JF Foley","year":"2019","unstructured":"Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord. 2019;31:65\u201371. https:\/\/doi.org\/10.1016\/j.msard.2019.03.017.","journal-title":"Mult Scler Relat Disord."},{"key":"953_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000672","volume":"7","author":"LZ Ryerson","year":"2020","unstructured":"Ryerson LZ, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7: e672. https:\/\/doi.org\/10.1212\/NXI.0000000000000672.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"953_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","volume":"24","author":"ZLE Van Kempen","year":"2018","unstructured":"Van Kempen ZLE, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, et al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2018;24:805\u201310. https:\/\/doi.org\/10.1177\/1352458517708464.","journal-title":"Mult Scler"},{"key":"953_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158978","volume":"11","author":"G Bsteh","year":"2016","unstructured":"Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, et al. Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study. PLoS\u00a0One. 2016;11: e0158978. https:\/\/doi.org\/10.1371\/journal.pone.0158978.","journal-title":"PLoS\u00a0One"},{"key":"953_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/1352458517753721","volume":"25","author":"F Deisenhammer","year":"2019","unstructured":"Deisenhammer F, Jank M, Lauren A, Sj\u00f6din A, Ryner M, Fogdell-Hahn A, ABIRISK consortium, et al. Prediction of natalizumab anti-drug antibodies persistency. Mult Scler. 2019;25:392\u20138. https:\/\/doi.org\/10.1177\/1352458517753721.","journal-title":"Mult Scler"},{"key":"953_CR17","volume-title":"Using multivariate statistics","author":"BG Tabachnick","year":"2007","unstructured":"Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. 5th ed. Boston: Pearson; 2007.","edition":"5"},{"key":"953_CR18","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395\u2013405. https:\/\/doi.org\/10.1093\/brain\/aww173.","journal-title":"Brain"},{"key":"953_CR19","unstructured":"Council National Research. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press (US); 2010."},{"key":"953_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2\u201318. https:\/\/doi.org\/10.1037\/a0024338.","journal-title":"J Exp Psychol Gen"},{"key":"953_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1468-1331.2006.01342.x","volume":"13","author":"M Pugliatti","year":"2006","unstructured":"Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V\u00e9csei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700\u201322. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01342.x.","journal-title":"Eur J Neurol"},{"key":"953_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s00415-005-0681-7","volume":"252","author":"P Rieckmann","year":"2005","unstructured":"Rieckmann P, Kruse N, Nagelkerken L, Beckmann K, Miller D, Polman C, et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. J Neurol. 2005;252:526\u201333. https:\/\/doi.org\/10.1007\/s00415-005-0681-7.","journal-title":"J Neurol"},{"key":"953_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.819911","volume":"13","author":"R Mancuso","year":"2022","unstructured":"Mancuso R, Agostini S, Hernis A, Caputo D, Galimberti D, Scarpini E, et al. Alterations of the miR-126-3p\/POU2AF1\/Spi-B axis and JCPyV reactivation in multiple sclerosis patients receiving natalizumab. Front Neurol. 2022;13: 819911. https:\/\/doi.org\/10.3389\/fneur.2022.819911.","journal-title":"Front Neurol"},{"key":"953_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5603\/PJNNS.a2022.0013","volume":"56","author":"M Jasiak-Zato\u0144ska","year":"2022","unstructured":"Jasiak-Zato\u0144ska M, Pietrzak A, Wyciszkiewicz A, Wi\u0119sik-Szewczyk E, Pawlak-Bu\u015b K, Leszczy\u0144ski P, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56:246\u201355. https:\/\/doi.org\/10.5603\/PJNNS.a2022.0013.","journal-title":"Neurol Neurochir Pol"},{"key":"953_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, AFFIRM and SENTINEL Investigators, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391\u2013403. https:\/\/doi.org\/10.1212\/01.wnl.0000277457.17420.b5.","journal-title":"Neurology"},{"key":"953_CR26","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","volume":"95","author":"ZLE Van Kempen","year":"2020","unstructured":"Van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020;95:e745\u201354. https:\/\/doi.org\/10.1212\/WNL.0000000000009995.","journal-title":"Neurology"},{"key":"953_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.716548","volume":"12","author":"JM Serra L\u00f3pez-Matencio","year":"2021","unstructured":"Serra L\u00f3pez-Matencio JM, P\u00e9rez Garc\u00eda Y, Meca-Lallana V, Ju\u00e1rez-S\u00e1nchez R, Ursa A, Vega-Piris L, et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses. Front Neurol. 2021;12: 716548. https:\/\/doi.org\/10.3389\/fneur.2021.716548.","journal-title":"Front Neurol"},{"key":"953_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1352458516684023","volume":"23","author":"ZLE Van Kempen","year":"2017","unstructured":"Van Kempen ZLE, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2017;23:995\u20139. https:\/\/doi.org\/10.1177\/1352458516684023.","journal-title":"Mult Scler"},{"key":"953_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","volume":"262","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Kinoshita M, Foley JF, Tanaka K, Kira J, Carroll WM. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol. 2015;262:781\u20132. https:\/\/doi.org\/10.1007\/s00415-015-7655-1.","journal-title":"J Neurol"},{"key":"953_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458512460604","volume":"19","author":"A Vennegoor","year":"2013","unstructured":"Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19:593\u2013600. https:\/\/doi.org\/10.1177\/1352458512460604.","journal-title":"Mult Scler"},{"key":"953_CR31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","volume":"89","author":"T Plavina","year":"2017","unstructured":"Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89:1584\u201393. https:\/\/doi.org\/10.1212\/WNL.0000000000004485.","journal-title":"Neurology"},{"key":"953_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0165-5728(01)00469-6","volume":"122","author":"J Kraus","year":"2002","unstructured":"Kraus J, Engelhardt B, Chatzimanolis N, Bauer R, Tofighi J, Kuehne BS, et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol. 2002;122:175\u201385. https:\/\/doi.org\/10.1016\/s0165-5728(01)00469-6.","journal-title":"J Neuroimmunol"},{"key":"953_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.549842","volume":"11","author":"K Khoy","year":"2020","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol. 2020;11: 549842. https:\/\/doi.org\/10.3389\/fimmu.2020.549842.","journal-title":"Front Immunol"},{"key":"953_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2016.09.001","volume":"10","author":"ER Petersen","year":"2016","unstructured":"Petersen ER, S\u00f8ndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, et al. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis. Mult Scler Relat Disord. 2016;10:66\u201372. https:\/\/doi.org\/10.1016\/j.msard.2016.09.001.","journal-title":"Mult Scler Relat Disord"},{"key":"953_CR35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/jpm11121347","volume":"11","author":"J Granell-Geli","year":"2021","unstructured":"Granell-Geli J, Izquierdo-Gracia C, Sell\u00e9s-Rius A, Teniente-Serra A, Presas-Rodr\u00edguez S, Mansilla MJ, et al. Assessing blood-based biomarkers to define a therapeutic window for natalizumab. J Pers Med. 2021;11:1347. https:\/\/doi.org\/10.3390\/jpm11121347.","journal-title":"J Pers Med"},{"issue":"314","key":"953_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jns.2011.10.005","volume":"15","author":"G Defer","year":"2012","unstructured":"Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci. 2012;15(314):138\u201342. https:\/\/doi.org\/10.1016\/j.jns.2011.10.005.","journal-title":"J Neurol Sci"},{"key":"953_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","volume":"16","author":"M Khademi","year":"2009","unstructured":"Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16:528\u201336. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02532.x.","journal-title":"Eur J Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00953-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00953-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00953-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T22:23:59Z","timestamp":1665440639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00953-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00953-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"31 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael Auer received speaker honoraria and\/or travel grants from Biogen, Merck, Novartis, and Sanofi Genzyme. Angelika Bauer, Antonia Oftring, and Dagmar Rudzki report no conflicts of interest. Harald Hegen has participated in meetings sponsored by and has received speaker honoraria or travel funding from Bayer, Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme, Siemens, and Teva, and received honoraria for consulting from Biogen, Celgene, Novartis, and Teva. Gabriel Bsteh has participated in meetings sponsored by and received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Novartis, Roche, Sanofi-Genzyme, and Teva. He has received unrestricted research grants from Celgene\/BMS and Novartis. Franziska Di Pauli has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene, and Roche. Klaus Berek has participated in meetings sponsored by and received travel funding from Roche, Biogen, and Teva. Anne Zinganell has participated in meetings sponsored by and received speaking honoraria or travel funding from Biogen, Merck, Sanofi-Genzyme, and Teva. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Celgene, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi Aventis, and Teva and for participation in clinical trials in MS sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva). Markus Reindl reports no conflicts of interest relating to the present article. Florian Deisenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor\/speaker for Alexion, Almirall, Biogen, Celgene, Merck, Novartis, Roche, and Sanofi-Genzyme. His institution received scientific grants from Biogen and Sanofi-Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Medical University of Innsbruck, Austria (approval number 1341\/2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For storage of samples, patients had to sign a written informed consent for the use of excess material for scientific purposes at the time of sampling.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data are available upon reasonable request from the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"MA: study concept and design, patient recruitment, acquisition and interpretation of data, statistical analysis, drafting of manuscript. AB: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. AO: performance of assays, acquisition and interpretation of data, critical revision of manuscript for intellectual content. DR: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. HH: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. GB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. FDP: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. KB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. AZ: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. TB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. MR: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. FD: study concept and design, patient recruitment, acquisition of data, interpretation of data, critical revision of manuscript for intellectual content, supervision. All authors have read and approve the final submitted version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}